Spanner In Works For UK Gov’t’s Brexit Plans; Industry Looks To Ongoing Talks With Ministers
Executive Summary
Parliament may get to vote on the terms of the UK’s departure from the EU if an important legal decision handed down today is upheld. Industry has its eye on ongoing talks with the government.
You may also be interested in...
‘We Want You To Stay,’ EU Agency Heads Tell UK
The role of the UK drug regulator in the EU post-Brexit will depend on the outcome of complex negotiations. It’s clear that the loss of the MHRA from the network would be keenly felt by other agencies across Europe.
UK Industry Welcomes R&D Measures In Chancellor’s Autumn Statement
Faced with a predicted sharp decline in economic growth as a result of the Brexit vote, the UK Chancellor of the Exchequer has fleshed out proposals for supporting R&D and innovation that have been welcomed by the biopharmaceutical industry.
UK Regulator Has Key Role in One in Four EU-Wide Approvals
The extent of the UK medicines regulator’s involvement in the European regulatory network shows how complicated disentangling the UK from the system would be.